The mechanisms behind the development of HTN from ramucirumab are similar to those described for other antiangiogenic agents and include: decreased production of nitric oxide in the wall of arterioles and other resistance vessels [17], increased activation of the endothelin-1 system [18], and/or capillary rarefaction [19]. Here, EDN1 is linked to hypertensive disorder.